BACKGROUND AND PURPOSE: The endothelium-derived hyperpolarizing factor (EDHF)-type relaxation in mesenteric small arteries from 21 week old Zucker lean (ZL) and Zucker diabetic fatty (ZDF) rats was investigated using (6,7-dichloro-1H-indole-2,3-dione 3-oxime) (NS309), a potent activator of small-conductance, calcium-activated potassium channel (SK(Ca)) and intermediate-conductance, calcium-activated potassium channel (IK(Ca)). EXPERIMENTAL APPROACH: In the presence of inhibitors of cyclooxygenase and nitric oxide synthase [indomethacin and N(omega)-nitro-L-arginine methyl ester (l-NAME), respectively], acetylcholine (ACh)-induced hyperpolarization and EDHF-type relaxation were investigated under isometric conditions in the wire myograph using 0.5 and 1 microM NS309 and/or selective blockers of SK(Ca) and IK(Ca) channels. Membrane potential was recorded with glass microelectrodes, and changes in the intracellular calcium concentration of endothelial cells were visualized by confocal microscopy. SK(Ca) expression was assessed by Western blotting. KEY RESULTS: In arteries from ZDF rats, ACh-induced relaxation and membrane hyperpolarization were attenuated and, compared with arteries from ZL rats, NS309 was less potent at causing relaxation. Incubation with 0.5 microM NS309 did not increase ACh-induced relaxation in arteries from ZDF rats significantly. However, 1 microM NS309 restored it (both in the absence and in the presence of indomethacin and l-NAME) without changing endothelial intracellular calcium concentration. The restored EDHF-type relaxation was more sensitive to TRAM-34 (1-[(2-chlorophenyl) diphenylmethyl]-1H-pyrazole) (1 microM) than to apamin. Expression of the SK(Ca) channel was unaltered. CONCLUSIONS AND IMPLICATIONS: The attenuated EDHF-type relaxation in mesenteric small arteries from ZDF rats can be restored by NS309 without changes in the intracellular calcium concentration of endothelial cells. These results may have clinical implications for the treatment of endothelial dysfunction in overweight type 2 diabetic patients.
BACKGROUND AND PURPOSE: The endothelium-derived hyperpolarizing factor (EDHF)-type relaxation in mesenteric small arteries from 21 week old Zucker lean (ZL) and Zucker diabetic fatty (ZDF) rats was investigated using (6,7-dichloro-1H-indole-2,3-dione 3-oxime) (NS309), a potent activator of small-conductance, calcium-activated potassium channel (SK(Ca)) and intermediate-conductance, calcium-activated potassium channel (IK(Ca)). EXPERIMENTAL APPROACH: In the presence of inhibitors of cyclooxygenase and nitric oxide synthase [indomethacin and N(omega)-nitro-L-arginine methyl ester (l-NAME), respectively], acetylcholine (ACh)-induced hyperpolarization and EDHF-type relaxation were investigated under isometric conditions in the wire myograph using 0.5 and 1 microM NS309 and/or selective blockers of SK(Ca) and IK(Ca) channels. Membrane potential was recorded with glass microelectrodes, and changes in the intracellular calcium concentration of endothelial cells were visualized by confocal microscopy. SK(Ca) expression was assessed by Western blotting. KEY RESULTS: In arteries from ZDFrats, ACh-induced relaxation and membrane hyperpolarization were attenuated and, compared with arteries from ZL rats, NS309 was less potent at causing relaxation. Incubation with 0.5 microM NS309 did not increase ACh-induced relaxation in arteries from ZDFrats significantly. However, 1 microM NS309 restored it (both in the absence and in the presence of indomethacin and l-NAME) without changing endothelial intracellular calcium concentration. The restored EDHF-type relaxation was more sensitive to TRAM-34 (1-[(2-chlorophenyl) diphenylmethyl]-1H-pyrazole) (1 microM) than to apamin. Expression of the SK(Ca) channel was unaltered. CONCLUSIONS AND IMPLICATIONS: The attenuated EDHF-type relaxation in mesenteric small arteries from ZDFrats can be restored by NS309 without changes in the intracellular calcium concentration of endothelial cells. These results may have clinical implications for the treatment of endothelial dysfunction in overweight type 2 diabeticpatients.
Authors: Rostislav Bychkov; Matthew P Burnham; Gillian R Richards; Gillian Edwards; Arthur H Weston; Michel Félétou; Paul M Vanhoutte Journal: Br J Pharmacol Date: 2002-12 Impact factor: 8.739
Authors: Lawrence J Coppey; Jill S Gellett; Eric P Davidson; Joyce A Dunlap; Mark A Yorek Journal: Diabetes Metab Res Rev Date: 2002 Jan-Feb Impact factor: 4.876
Authors: M P Burnham; R Bychkov; M Félétou; G R Richards; P M Vanhoutte; A H Weston; G Edwards Journal: Br J Pharmacol Date: 2002-03 Impact factor: 8.739
Authors: Kim A Dora; Shaun L Sandow; Nicola T Gallagher; Hiromichi Takano; Nicole M Rummery; Caryl E Hill; Chris J Garland Journal: J Vasc Res Date: 2003-10-28 Impact factor: 1.934
Authors: Mark S Taylor; Adrian D Bonev; Tobias P Gross; Delrae M Eckman; Joseph E Brayden; Chris T Bond; John P Adelman; Mark T Nelson Journal: Circ Res Date: 2003-06-12 Impact factor: 17.367
Authors: Cini Mathew John; Rayan Khaddaj Mallat; Ramesh C Mishra; Grace George; Vikrant Singh; Jeannine D Turnbull; Channakeshava S Umeshappa; Dylan J Kendrick; Taeyeob Kim; Fazlin M Fauzi; Frank Visser; Paul W M Fedak; Heike Wulff; Andrew P Braun Journal: Pharmacol Res Date: 2019-11-07 Impact factor: 7.658